Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational studyResearch in context
Summary: Background: About 15–20% of breast cancers (BC) overexpress Human Epidermal Growth Factor Receptor 2 (HER2+), and 50% of them are also oestrogen receptor positive (ER+). Patients with ER+/HER2+ BC with a limited response to systemic therapies are at an increased risk of relapse, thus under...
Saved in:
| Main Authors: | Milana Bergamino Sirvén, Elena López-Knowles, Xixuan Zhu, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, John Robertson, Judith M. Bliss, Anastasia Alataki, Ian Smith, Eugene F. Schuster, Mitch Dowsett, Maggie Chon U. Cheang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396425002671 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning
by: Oana Maria Burciu, et al.
Published: (2025-07-01) -
Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study
by: Iokfai Cheang, et al.
Published: (2025-07-01) -
Benefits of aromatase blockers for increased testosterone in poultry: A mini-review
by: Rizki Fitrawan Yuneldi, et al.
Published: (2025-05-01) -
Postmarketing assessment of a switchable similar anastrozole product in Brazilian breast cancer patients
by: Manuela Vasquez Cardoso, et al.
Published: (2023-04-01) -
Discovery to Engineering of Mycotoxin Deoxynivalenol Degrading Enzymes Based on the Specialized Glyoxalase I
by: Seung Hee Lee, et al.
Published: (2025-08-01)